A compound called Trabid that regulates protein use could be a promising target for developing novel treatments for patients with multiple sclerosis.
A protein regulator called Trabid may unlock future multiple sclerosis (MS) treatments, according to findings published in Nature Immunology. Researchers from the University of Texas MD Anderson Cancer Center determined that Trabid – protein regulator used to autoimmune inflammation in the central nervous system in MS – is a factor in managing the cytokine genes and the immune cell response.
“Our findings highlight an epigenetic mechanism for the regulation of the cytokine genes, interleukin 12 (IL 12) and interleukin 23 (IL 23), and established Trabid as an immunological regulator of inflammatory T cell responses,” Shao-Cong Sun, PhD, professor of Immunology, explained in a press release. “Trabid appeared to regulate histone modifications by controlling the fate of a histone demethylase called Jmjd2d.”
The researchers explained that cytokines are the small proteins which indicate cell signaling. They added that IL 12 and IL 23 part of the mediation system of inflammation in connection with inflammatory diseases.
Sun said that Trabid and Jmjd2d are potentially future therapeutic targets for inflammatory diseases such as MS.
Read Full Article: Impaired Cytokines Prohibits Multiple Sclerosis Development
|Read Full Article: Impaired Cytokines Prohibits Multiple Sclerosis Development|